ClinicalTrials.Veeva

Menu

Screening for Chronic Liver Diseases in General Population (HEPGEN)

University Hospital Center (CHU) logo

University Hospital Center (CHU)

Status

Not yet enrolling

Conditions

Fibrosis, Liver

Treatments

Diagnostic Test: Blood sample then fibroscan

Study type

Interventional

Funder types

Other

Identifiers

NCT06366425
RECHMPL23_0272

Details and patient eligibility

About

Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.

Full description

The prevalence of chronic liver diseases continues to increase on the one hand by the increase in non-alcoholic fatty liver disease (NAFLD) which affects 25% of the general population as well as the increased incidence of hepatocellular carcinoma in recent years. Screening for liver fibrosis in the general population represents a major public health issue.

The FIB-4 score is obtained by a blood test. This score combines age, measurement of ALT/ASAT (alanine aminotransferase / aspartate-aminotransferase) and platelet count. This score is sensitive for detecting advanced fibrosis liver and allows 71% of patients to avoid a liver biopsy.

Transient elastometry (Fibroscan®) is another very effective non-invasive assessment in the diagnosis of chronic liver diseases and hepatic fibrosis. It has already been demonstrated by several studies that combining several non-invasive fibrosis tests allows to improve the precision of the result.

The investigators hypothesize that offering an additional assessment by Fibroscan for patients screened by a blood test (FIB-4 Score) as possibly having advanced liver fibrosis (Score >2.67) will raise awareness among professional practitioners and the general population with chronic liver diseases and refine screening for chronic liver diseases.

Enrollment

260 estimated patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 40 years
  • Without known liver pathologies
  • Having at least one risk factor for chronic liver disease: risky consumption of alcoholic beverages according to the AUDIT questionnaire, the presence of metabolic syndrome, diabetes or a risk factor for viral hepatitis B, D or C.

Exclusion criteria

  • Fibroscan already performed in the last 12 months
  • Failure to collect express oral consent
  • Patient not affiliated with or not benefiting from a national health insurance scheme
  • Patient protected by law
  • Patient under guardianship or curatorship
  • Patient deprived of liberty
  • Pregnant or breastfeeding woman

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

260 participants in 1 patient group

Population with a chronic liver disease risk factor
Other group
Description:
Patient aged ≥ 40 years, with no known liver disease, consulting a general practitioner and having at least one risk factor for chronic liver disease: risky consumption of alcoholic beverages according to the AUDIT questionnaire, the presence of a metabolic syndrome, diabetes or a risk factor for viral hepatitis B/D or C.
Treatment:
Diagnostic Test: Blood sample then fibroscan

Trial contacts and locations

1

Loading...

Central trial contact

Magdalena MESZAROS, MD; Corinne ROTROU, CRA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems